{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:34Z","timestamp":1791489634806,"version":"4.3.4"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":244,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270183"],"award-info":[{"award-number":["82270183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101425","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:22:27Z","timestamp":1789204947000},"page":"101425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Relapse and progression after CAR-T cell therapy in large B-cell lymphoma: Patterns, mechanisms, and salvage strategies"],"prefix":"10.1016","volume":"49","author":[{"given":"Lingzhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101425_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1059914","article-title":"The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends","volume":"13","author":"Chu","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101425_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101425_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7056","article-title":"Global burden, risk factors, and trends of non-Hodgkin lymphoma: a worldwide analysis of cancer registries","volume":"13","author":"Huang","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2026.101425_bib0004","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Non-Hodgkin Lymphoma. National Cancer Institute. (2025). Accessed 2025 Oct 26, https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html."},{"issue":"10438","key":"10.1016\/j.ctarc.2026.101425_bib0005","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101425_bib0006","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101425_bib0007","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101425_bib0008","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Diffuse Large B-Cell Lymphoma (Version 2.2025). National Comprehensive Cancer Network. (2025). Accessed 2025 Oct 26, https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/nhl-diffuse-patient.pdf."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101425_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061453","article-title":"DLBCL 1L-what to expect beyond R-CHOP?","volume":"14","author":"Stegemann","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/2278-330X.126531","article-title":"Management of relapsed-refractory diffuse large B cell lymphoma","volume":"3","author":"Raut","year":"2014","journal-title":"South Asian J. Cancer"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101425_bib0011","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101425_bib0013","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.18197","article-title":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients","volume":"198","author":"Harrysson","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"26","key":"10.1016\/j.ctarc.2026.101425_bib0014","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101425_bib0016","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"New Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101425_bib0017","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101425_bib0018","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"New Engl. J. Med."},{"issue":"10343","key":"10.1016\/j.ctarc.2026.101425_bib0019","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2026.101425_bib0020","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood-2024-200204","article-title":"Five-year survival of patients (pts) from transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"144","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101425_bib0021","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.ctarc.2026.101425_bib0022","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101425_bib0023","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101425_bib0024","article-title":"Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma","volume":"11","author":"Negishi","year":"2023","journal-title":"Front. Pediatr."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101425_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/1744666X.2024.2349738","article-title":"Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy","volume":"20","author":"Dreyzin","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.ctarc.2026.101425_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106742","article-title":"Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: a definite evidence from systematic review and meta-analysis on individual data","volume":"190","author":"Zinzi","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ctarc.2026.101425_bib0027","article-title":"An AI model classifies risks of early relapse post-CAR T cell therapy in a multi-center real-world population with DLBCL","author":"Wang","year":"2025","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101425_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.08.026","article-title":"Impact of SCHOLAR-1 criteria on chimeric antigen receptor T cell therapy efficacy in aggressive B lymphoma: a real-world GELTAMO\/GETH study","volume":"29","author":"Bastos-Oreiro","year":"2023","journal-title":"Transplant. Cell Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0029","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101425_bib0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101425_bib0031","article-title":"Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR-T cell therapy: a Descar-T study by Lysa group","author":"Aymard","year":"2025","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101425_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis","volume":"8","author":"O'Reilly","year":"2024","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101425_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70146","article-title":"Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: a study on behalf of the EBMT and the GoCART coalition","volume":"9","author":"Ossami Saidy","year":"2025","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101425_bib0034","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ajh.70027","article-title":"CD19 directed CAR T therapy for transformed follicular lymphoma: a CIBMTR analysis","volume":"100","author":"Thiruvengadam","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ctarc.2026.101425_bib0035","article-title":"Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry","author":"Erbella","year":"2025","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101425_bib0036","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/ejh.14078","article-title":"Three cases of late-onset post CAR-T therapy isolated CNS relapse in R\/R large B-cell lymphoma","volume":"112","author":"Zhu","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101425_bib0037","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3324\/haematol.2023.282804","article-title":"Salvage radiotherapy in relapsed\/refractory large B-cell lymphoma after failure of CAR T-cell therapy","volume":"108","author":"Ababneh","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0038","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-025-01273-1","article-title":"CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma","volume":"15","author":"Luna","year":"2025","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101425_bib0039","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/cyt.13160","article-title":"Now you see me, now you don't: isolated central nervous system recurrence of CD19-negative diffuse large B-cell lymphoma following CD19-directed CAR T-cell treatment","volume":"33","author":"Gokozan","year":"2022","journal-title":"Cytopathology"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101425_bib0040","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101425_bib0041","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/ejh.13964","article-title":"Current perspectives on resistance to chimeric antigen receptor T-cell therapy and strategies to improve efficacy in B-cell lymphoma","volume":"112","author":"Ong","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101425_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"14","key":"10.1016\/j.ctarc.2026.101425_bib0043","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-23-1962","article-title":"Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma","volume":"30","author":"Lownik","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101425_bib0044","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12308-024-00602-w","article-title":"Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy","volume":"17","author":"Torabi","year":"2024","journal-title":"J. Hematop."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0046","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","article-title":"Strategies to enhance CAR-T persistence","volume":"10","author":"Liu","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ctarc.2026.101425_bib0047","article-title":"The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0048","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41419-025-07610-3","article-title":"The transition between M1 and M2 macrophage phenotypes is associated with the disease status following CD19 CAR-T therapy for B cell lymphoma\/leukemia","volume":"16","author":"Zhao","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0049","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-024-01608-8","article-title":"Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment","volume":"17","author":"Iacoboni","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101425_bib0050","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101425_bib0051","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101425_bib0052","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101425_bib0053","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant. Cell Ther."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101425_bib0054","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-024-01608-8","article-title":"Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment","volume":"17","author":"Iacoboni","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101425_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184671","article-title":"Outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma (LBCL): a single-institution experience","volume":"15","author":"Trando","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101425_bib0057","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101425_bib0058","article-title":"Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101425_bib0059","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2024025366","article-title":"Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy","volume":"145","author":"Prasad","year":"2025","journal-title":"Blood"},{"issue":"7480","key":"10.1016\/j.ctarc.2026.101425_bib0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation","volume":"504","author":"Arpaia","year":"2013","journal-title":"Nature"},{"issue":"6371","key":"10.1016\/j.ctarc.2026.101425_bib0061","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2026.101425_bib0062","doi-asserted-by":"crossref","unstructured":"Seok J. Kim S.Y., W. Kang. 1595 gut microbiome composition as a prognostic marker in CD19-targeting CAR T-cell therapy for relapsed\/refractory diffuse large B-cell lymphoma. 2024.","DOI":"10.1182\/blood-2024-205074"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101425_bib0063","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1631\/jzus.B2200256","article-title":"Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches","volume":"23","author":"Gu","year":"2022","journal-title":"J. Zhejiang Univ. Sci. B"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0064","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ctarc.2026.101425_bib0065","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101425_bib0066","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101425_bib0067","article-title":"Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma","volume":"13","author":"Junkuhn","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101425_bib0068","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jtct.2025.01.001","article-title":"Reduced chimeric antigen receptor T cell expansion postinfusion is associated with poor survival in patients with large B cell lymphoma after two or more therapies","volume":"31","author":"Abadir","year":"2025","journal-title":"Transplant. Cell Ther."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101425_bib0069","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41409-025-02539-9","article-title":"Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma","volume":"60","author":"Canelo-Vilaseca","year":"2025","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.16541","article-title":"Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy","volume":"190","author":"Imber","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2026.101425_bib0071","doi-asserted-by":"crossref","DOI":"10.1177\/15330338251351065","article-title":"The role of radiotherapy in relapsed or refractory diffuse large B-cell lymphoma post-CAR-T therapy: a systematic literature review","volume":"24","author":"Guerini","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101425_bib0072","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","article-title":"Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas","volume":"5","author":"Liebers","year":"2021","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101425_bib0073","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101425_bib0074","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/bloodadvances.2022009025","article-title":"Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy","volume":"7","author":"Furqan","year":"2023","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101425_bib0075","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/bloodadvances.2021006801","article-title":"A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy","volume":"6","author":"Gouni","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ctarc.2026.101425_bib0076","doi-asserted-by":"crossref","unstructured":"Paolo F. Caimi K.M.A., Erin R.. The anti-CD19 antibody-drug conjugate loncastuximab tesirine achieved responses in patients with diffuse large B-cell lymphoma who relapsed after anti-CD19 CAR T-cell 2021.","DOI":"10.1182\/blood-2021-153591"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101425_bib0077","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/jha2.993","article-title":"Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine","volume":"5","author":"Hamadani","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.ctarc.2026.101425_bib0078","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211027458","article-title":"The use of tafasitamab in diffuse large B-cell lymphoma","volume":"12","author":"D\u00fcll","year":"2021","journal-title":"Ther. Adv. Hematol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101425_bib0079","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/oncolo\/oyac256","article-title":"Clinical treatment guidelines for tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"28","author":"Nedved","year":"2023","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101425_bib0080","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101425_bib0081","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/bloodadvances.2024013726","article-title":"Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy","volume":"8","author":"Camus","year":"2024","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101425_bib0082","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41409-023-02148-4","article-title":"Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy","volume":"59","author":"Iqbal","year":"2024","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101425_bib0083","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: t-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101425_bib0084","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ctarc.2026.101425_bib0085","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101425_bib0086","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101425_bib0087","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1641769","article-title":"CD20\u00d7CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis","volume":"15","author":"Shen","year":"2025","journal-title":"Front. Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101425_bib0088","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101425_bib0089","doi-asserted-by":"crossref","DOI":"10.3390\/cells11172747","article-title":"Experiences with glofitamab administration following CAR T therapy in patients with relapsed mantle cell lymphoma","volume":"11","author":"Heini","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101425_bib0090","first-page":"244","article-title":"The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy","volume":"8","author":"Shimakawa","year":"2025","journal-title":"Blood Cell Ther."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101425_bib0091","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-21-0515","article-title":"Reversing T-cell exhaustion in cancer: lessons learned from PD-1\/PD-L1 immune checkpoint blockade","volume":"10","author":"Budimir","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"1\u20132","key":"10.1016\/j.ctarc.2026.101425_bib0092","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1615\/ForumImmunDisTher.2015014188","article-title":"Reinvigorating exhausted T cells by blockade of the PD-1 pathway","volume":"6","author":"Lee","year":"2015","journal-title":"For. Immunopathol. Dis. Ther."},{"key":"10.1016\/j.ctarc.2026.101425_bib0093","article-title":"Axicabtagene ciloleucel in combination with atezolizumab in patients with refractory diffuse large B-cell lymphoma: the phase 1\/2 ZUMA-6 trial","author":"Jacobson","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101425_bib0094","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101425_bib0095","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/bloodadvances.2023010016","article-title":"Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions","volume":"7","author":"Major","year":"2023","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101425_bib0096","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101425_bib0097","first-page":"898.e1","article-title":"Treatment of diffuse large B-cell lymphoma progressing or relapsing after chimeric antigen receptor T-cell therapy","volume":"31","author":"Kharfan-Dabaja","year":"2025","journal-title":"Transplant. Cell. Ther. Off. Publ. Am. Soc. Transplant. Cell. Ther."},{"key":"10.1016\/j.ctarc.2026.101425_bib0098","article-title":"Case report: dual inhibition of HDAC and BTK for diffuse large B-cell lymphoma after failure to CD19-targeted CAR-T therapy","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101425_bib0099","doi-asserted-by":"crossref","first-page":"342.e1","DOI":"10.1016\/j.jtct.2022.02.021","article-title":"Assessment of salvage regimens post-chimeric antigen receptor T cell therapy for patients with diffuse large B cell lymphoma","volume":"28","author":"Sigmund","year":"2022","journal-title":"Transplant. Cell. Ther."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101425_bib0100","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/onco.13859","article-title":"FDA approval summary: selinexor for relapsed or refractory diffuse large B-cell lymphoma","volume":"26","author":"Kasamon","year":"2021","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101425_bib0101","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.62347\/RKWU3795","article-title":"Selinexor combined with R-GDP as salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"15","author":"Jiang","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101425_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101459","article-title":"Resistance against anti-CD19 and anti-BCMA CAR T cells: recent advances and coping strategies","volume":"22","author":"Atilla","year":"2022","journal-title":"Transl. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101425_bib0103","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MOH.0000000000000548","article-title":"Mechanisms of failure of chimeric antigen receptor T-cell therapy","volume":"26","author":"Li","year":"2019","journal-title":"Curr. Opin. Hematol."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101425_bib0104","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26199669","article-title":"Limitations of CAR-T-cell therapy in hematologic malignancies: focusing on antigen escape and T-cell dysfunction","volume":"26","author":"Lin","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101425_bib0105","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/bloodadvances.2025016727","article-title":"Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry","volume":"10","author":"Erbella","year":"2026","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101425_bib0106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011549","article-title":"CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy","volume":"13","author":"Myers","year":"2025","journal-title":"J. ImmunoTher. Cancer"},{"issue":"20","key":"10.1016\/j.ctarc.2026.101425_bib0107","first-page":"2470","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"issue":"10450","key":"10.1016\/j.ctarc.2026.101425_bib0108","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101425_bib0109","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12967-023-04019-4","article-title":"Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy","volume":"21","author":"Li","year":"2023","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101425_bib0111","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-2141.2009.07886.x","article-title":"The allogeneic graft-versus-cancer effect","volume":"147","author":"Ringd\u00e9n","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2026.101425_bib0112","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2017.00496","article-title":"Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia","volume":"8","author":"Dickinson","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101425_bib0113","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtct.2022.10.026","article-title":"Allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy in large B cell lymphoma","volume":"29","author":"Fried","year":"2023","journal-title":"Transplant. Cell. Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0114","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101425_bib0115","doi-asserted-by":"crossref","first-page":"898.e1","DOI":"10.1016\/j.jtct.2025.08.008","article-title":"Treatment of diffuse large B-cell lymphoma progressing or relapsing after chimeric antigen receptor T-cell therapy","volume":"31","author":"Kharfan-Dabaja","year":"2025","journal-title":"Transplant. Cell. Ther."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101425_bib0116","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/bjh.70010","article-title":"Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: feasibility, safety and survival outcomes","volume":"207","author":"Barone","year":"2025","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101425_bib0117","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40164-024-00473-y","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation in R\/R DLBCL patients with failure of CAR-T therapy","volume":"13","author":"Cong","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101425_bib0118","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1182\/bloodadvances.2025016141","article-title":"Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR","volume":"9","author":"Wudhikarn","year":"2025","journal-title":"Blood Adv."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:45:22Z","timestamp":1791488722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":118,"alternative-id":["S2468294226003357"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101425","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relapse and progression after CAR-T cell therapy in large B-cell lymphoma: Patterns, mechanisms, and salvage strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101425"}}